265 related articles for article (PubMed ID: 31137964)
41. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
Iannello A; Vitale N; Coma S; Arruga F; Chadburn A; Di Napoli A; Laudanna C; Allan JN; Furman RR; Pachter JA; Deaglio S; Vaisitti T
Blood; 2021 Jun; 137(24):3378-3389. PubMed ID: 33786583
[TBL] [Abstract][Full Text] [Related]
42. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
Chen SS; Barrientos JC; Ferrer G; King-Richards M; Chen YJ; Ravichandran P; Ibrahim M; Kieso Y; Waters S; Kutok JL; Peluso M; Sharma S; Weaver DT; Pachter JA; Rai KR; Chiorazzi N
Clin Cancer Res; 2023 May; 29(10):1984-1995. PubMed ID: 37071496
[TBL] [Abstract][Full Text] [Related]
43. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
44. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
45. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
46. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
47. Duvelisib in haematological malignancies.
Das M
Lancet Oncol; 2018 Nov; 19(11):e586. PubMed ID: 30318318
[No Abstract] [Full Text] [Related]
48. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
Patel K; Danilov AV; Pagel JM
Blood; 2019 Nov; 134(19):1573-1577. PubMed ID: 31554637
[TBL] [Abstract][Full Text] [Related]
49. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
[TBL] [Abstract][Full Text] [Related]
50. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
51. A phase 2 study of ofatumumab (Arzerra
Chen CI; Paul H; Le LW; Wei EN; Snitzler S; Wang T; Levina O; Kakar S; Lau A; Queau M; Johnston JB; Smith DA; Trudel S
Leuk Lymphoma; 2019 Jan; 60(1):92-100. PubMed ID: 29916761
[TBL] [Abstract][Full Text] [Related]
52. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
53. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Chung C; Lee R
Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
[TBL] [Abstract][Full Text] [Related]
54. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Flinn IW; Patel M; Oki Y; Horwitz S; Foss FF; Allen K; Douglas M; Stern H; Sweeney J; Kharidia J; Kelly P; Kelly VM; Kahl B
Am J Hematol; 2018 Nov; 93(11):1311-1317. PubMed ID: 30033575
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Mato AR; Nabhan C; Barr PM; Ujjani CS; Hill BT; Lamanna N; Skarbnik AP; Howlett C; Pu JJ; Sehgal AR; Strelec LE; Vandegrift A; Fitzpatrick DM; Zent CS; Feldman T; Goy A; Claxton DF; Bachow SH; Kaur G; Svoboda J; Nasta SD; Porter D; Landsburg DJ; Schuster SJ; Cheson BD; Kiselev P; Evens AM
Blood; 2016 Nov; 128(18):2199-2205. PubMed ID: 27601462
[TBL] [Abstract][Full Text] [Related]
56. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
[TBL] [Abstract][Full Text] [Related]
57. A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
Eyre TA; Preston G; Kagdi H; Islam A; Nicholson T; Smith HW; Cursley AP; Ramroth H; Xing G; Gu L; Rajakumaraswamy N; Fegan C
Br J Haematol; 2021 Jul; 194(1):69-77. PubMed ID: 34121184
[TBL] [Abstract][Full Text] [Related]
58. [New European approval: Duvelisib - relapsed/refractory CLL and follicular lymphoma].
Fornero L; Lamure S
Bull Cancer; 2021 Oct; 108(10):906-907. PubMed ID: 34607678
[No Abstract] [Full Text] [Related]
59. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Brown JR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):807-826. PubMed ID: 34174987
[TBL] [Abstract][Full Text] [Related]
60. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
Langerbeins P; Bahlo J; Rhein C; Cramer P; Pflug N; Fischer K; Stilgenbauer S; Kreuzer KA; Wendtner CM; Eichhorst B; Hallek M
Future Oncol; 2015; 11(13):1895-903. PubMed ID: 26161926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
